Analyzing the therapeutic impact of di-ABZI on PBRM1-deficient ccRCC Tumors

- Type I interferon is a central tumor suppressing pathway in ccRCC Tumors
Multi-regional Sequencing Elucidates the Evolution of Clear Cell Renal Cell Carcinoma. Ricketts CJ\(^1\), Linehan WM\(^2\).
VHL represses IFN-β expression in ccRCC cells. HIF2alpha induces it.
PBRM1 is required to maintain ISGF3 activity

(data from collaborator William Kim at UNC Chapel Hill)
ISGF3 is tumor suppressive in ccRCC cells

Genetic activation of ISGF3 is strongly tumor suppressive in different models
Pharmacological activation of ISGF3 elicits strong anti-tumor responses in PBRM1-deficient xenograft models.
Acknowledgement:

Collaborators:
Qin Yan, Yale
Wei Jiang, Jon Brody, Jefferson
William Kim, UNC

Robert Uzzo,
Joseph Testa,
Fox Chase Cancer Center

Ph.D. mentor:
Dick Hallberg Ph.D.

Postdoc mentor:
William G. Kaelin Jr. M.D.

Chair
Stephen Peiper M.D.

Lab members:
Liang Zhou, PhD (Postdoc)
Lili Liao, PhD (Postdoc)
Xiaohua Niu, MD PhD (Postdoc)
Ting Zhang, M.D. (Graduate student)
Eun-Ah Cho PhD (Postdoc)
Weijia Cai PhD (Postdoc)
Qiong Wang MD PhD (visiting scholar)
Rayan El Hajjar MD (visiting scholar)
Lauren Langbein (Graduate student)
Rita Moukarzel (Res. Associate)

Funding: American Cancer Society, VHL Alliance, NIH/NCI, KCCure, KCA, DOD KCRP